Last month, 10-year-old Josh Housley was diagnosed with Hodgkin’s lymphoma. Josh is at home fighting cancer and undergoing aggressive chemotherapy.
His classmates in the fourth-grade at Grassland Elementary decided they wanted to help Josh through this difficult time, so all the male students went on a field trip to the barber shop. Although Josh can't enjoy time with his friends, he's not too far from their thoughts. Since Josh has lost his hair because of chemotherapy, they decided to save their heads to support him.
“I'm very proud of my kids. Just look around,” the teacher said.
“We didn't want to leave Josh out, so we thought it'd be pretty good to support him,” a friend said.
“I think I made a new fashion statement at the school,” Josh said. “If they want to make me happy, they just did it."
Josh will spend most of the summer in chemotherapy, but he has a great attitude and said he's ready to do it and get it over with.
Most of the fourth-grade boys said they'll keep their buzz cuts until Josh grows his hair back. After all, they said it's cool and they're enjoying the extra attention. WTVF Nashville
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...